Climb Bio reports positive Phase 1 safety data for CLYM116; plans Phase 2 in IgAN in Q3 2026

Climb Bio, Inc.

Translational PK/PD model from NHP data projects dose-dependent IgA suppression, suggesting less-frequent dosing.
Preliminary safety from 49 healthy volunteers (single doses up to 320 mg): no SAEs, DLTs, or discontinuations; all AEs mild-moderate and transient.
Partner Mabworks to initiate Phase 2 dosing in IgAN patients in Q3 2026 in China.
Company plans to advance CLYM116 into further clinical development based on data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.